Unnamed: 0,title,date,stock,sentiment
954389.0,Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress  Jun. 11-14,2020-05-14 09:07:00-04:00,OMER,neutral
954390.0,"Omeros Q1 EPS $(0.530) Misses $(0.340) Estimate, Sales $23.537M Miss $30.270M Estimate",2020-05-11 16:12:00-04:00,OMER,negative
954391.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,OMER,neutral
954392.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,OMER,neutral
954393.0,85 Biggest Movers From Yesterday,2020-03-04 05:04:00-05:00,OMER,neutral
954394.0,Mid-Afternoon Market Update: Dow Tumbles 800 Points; Superconductor Technologies Shares Spike Higher,2020-03-03 14:50:00-05:00,OMER,positive
954395.0,Mid-Day Market Update: Dow Falls Over 200 Points; Fed Issues Emergency Interest Rate Cut,2020-03-03 12:17:00-05:00,OMER,negative
954396.0,50 Stocks Moving In Tuesday's Mid-Day Session,2020-03-03 12:03:00-05:00,OMER,neutral
954397.0,Omeros shares are trading higher after the company reported Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.,2020-03-03 10:27:00-05:00,OMER,positive
954398.0,Mid-Morning Market Update: Markets Open Higher; Target Posts Mixed Q4 results,2020-03-03 10:14:00-05:00,OMER,neutral
954399.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,OMER,positive
954400.0,40 Stocks Moving in Tuesday's Pre-Market Session,2020-03-03 07:31:00-05:00,OMER,neutral
954401.0,15 Stocks Moving In Monday's After-Hours Session,2020-03-02 16:50:00-05:00,OMER,neutral
954402.0,Omeros shares are trading higher after the company reported  Narsoplimab HSCT-TMA results surpassed the FDA-agreed efficacy threshold.,2020-03-02 16:08:00-05:00,OMER,positive
954403.0,"Omeros Q4 EPS $(0.58) Misses $(0.5) Estimate, Sales $33.417M Beat $31.57M Estimate",2020-03-02 16:03:00-05:00,OMER,negative
954404.0,Omeros Offers Updated Results From Narsoplimab HSCT-TMA Trial: 'Results Surpass FDA-Agreed Efficacy Threshold',2020-03-02 16:02:00-05:00,OMER,neutral
954405.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,OMER,neutral
954406.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,OMER,negative
954407.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,OMER,neutral
954408.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,OMER,negative
954409.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,OMER,negative
954410.0,Stocks That Hit 52-Week Lows On Monday,2020-02-03 11:53:00-05:00,OMER,negative
954411.0,Stocks That Hit 52-Week Lows On Friday,2020-01-31 11:00:00-05:00,OMER,negative
954412.0,myTomorrows And Omeros Corporation Collaborate To Provide An Expanded Access Program For Narsoplimab,2019-12-18 08:42:00-05:00,OMER,neutral
954413.0,Omeros Highlights Presentation Of GPR174 Immuno-Oncology Data At ESMO Immuno-Oncology Congress Showing Inhibition Of Both Checkpoint And Tumor-Promoting Factors,2019-12-16 08:41:00-05:00,OMER,negative
954414.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,OMER,neutral
954415.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-12-05 12:07:00-05:00,OMER,neutral
954416.0,Omeros shares are trading lower after the company reported a proposed public offering of common stock priced in the $13.10-$13.40 per share range.,2019-12-05 08:19:00-05:00,OMER,positive
954417.0,17 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-05 07:55:00-05:00,OMER,neutral
954418.0,40 Stocks Moving in Thursday's Pre-Market Session,2019-12-05 07:30:00-05:00,OMER,neutral
954419.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,OMER,positive
954420.0,7 Stocks Moving In Wednesday's After-Hours Session,2019-12-04 18:08:00-05:00,OMER,neutral
954421.0,Omeros shares are trading lower after the company reported a proposed public offering of common stock priced in the $13.10-$13.40 per share range.,2019-12-04 16:28:00-05:00,OMER,positive
954422.0,Hearing Omeros Shares Priced In $13.10-$13.40/Share Range For Offering,2019-12-04 16:22:00-05:00,OMER,positive
954423.0,"Omeros Reports Common Stock Offering, No Size Disclosed",2019-12-04 16:13:00-05:00,OMER,negative
954424.0,Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab,2019-12-04 10:42:00-05:00,OMER,neutral
954425.0,Omeros Announces Results Of Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab,2019-12-04 07:03:00-05:00,OMER,neutral
954426.0,"H.C. Wainwright Reiterates Buy on Omeros, Lowers Price Target to $34",2019-12-02 07:16:00-05:00,OMER,negative
954427.0,Omeros Presents New GPR174 Immuno-Oncology Data At American Association For Cancer Research Conference In Boston,2019-11-19 08:48:00-05:00,OMER,negative
954428.0,"Omeros Q3 EPS $(0.33) Beats $(0.41) Estimate, Sales $29.856M Beat $27.24M Estimate",2019-11-12 16:44:00-05:00,OMER,neutral
954429.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,OMER,neutral
954430.0,46 Biggest Movers From Yesterday,2019-11-05 04:45:00-05:00,OMER,neutral
954431.0,35 Stocks Moving In Monday's Mid-Day Session,2019-11-04 13:37:00-05:00,OMER,neutral
954432.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,OMER,neutral
954433.0,21 Stocks Moving In Monday's Pre-Market Session,2019-11-04 07:56:00-05:00,OMER,neutral
954434.0,Omeros Reports Narsoplimab Receives Positive Opinion From EMA,2019-10-29 09:03:00-04:00,OMER,positive
954435.0,Omeros Corporation Initiates BLA Submission For Narsoplimab For The Treatment Of HSCT-TMA,2019-10-28 08:59:00-04:00,OMER,neutral
954436.0,Omeros Reports Results From Phase 1 Study Of OMS527 In Development For Addiction,2019-09-16 08:46:00-04:00,OMER,neutral
954437.0,Omeros Highlights Ability Of GPR174 Inhibitors In Anti-Tumor Activities,2019-09-10 08:37:00-04:00,OMER,positive
954438.0,27 Stocks Moving in Monday's Pre-Market Session,2019-08-19 08:12:00-04:00,OMER,neutral
954439.0,90 Biggest Movers From Friday,2019-08-12 05:49:00-04:00,OMER,neutral
954440.0,75 Stocks Moving In Friday's Mid-Day Session,2019-08-09 14:06:00-04:00,OMER,neutral
954441.0,52 Stocks Moving In Friday's Pre-Market Session,2019-08-09 08:30:00-04:00,OMER,neutral
954442.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,OMER,neutral
954443.0,Omeros shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-08 16:04:00-04:00,OMER,positive
954444.0,"Omeros Q2 EPS $(0.29) Beats $(0.46) Estimate, Sales $26.753M Beat $24.52M Estimate",2019-08-08 16:03:00-04:00,OMER,neutral
954445.0,"Omeros Reports Long-Term Manufacturing Deal With Lonza For Commercial Supply For Narsoplimab, No Terms Disclosed",2019-07-31 08:31:00-04:00,OMER,negative
954446.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,OMER,neutral
954447.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-07-11 12:50:00-04:00,OMER,neutral
954448.0,"Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment",2019-07-11 10:23:00-04:00,OMER,negative
954449.0,Omeros shares are trading higher after the company announced an agreement with the FDA on the primary endpoint for its trial of Narsoplimab BLA in stem cell transplant-associated TMA.,2019-07-11 08:45:00-04:00,OMER,positive
954450.0,Omeros Reports FDA Deal On Primary Endpoint For Narsoplimab Biologics License Application In Stem Cell Transplant-Associated TMA,2019-07-11 08:04:00-04:00,OMER,neutral
954451.0,CORRECTION: Omeros Shares Trading Higher; Recent Headline Which Was Published Incorrectly Suggested Stock Was Lower; However Shares Had Opened Lower This Morning,2019-05-10 11:17:00-04:00,OMER,neutral
954452.0,Omeros shares are trading lower after the company reported worse-than-expected Q1 EPS results.,2019-05-09 16:51:00-04:00,OMER,neutral
954453.0,Omeros Q1 EPS $(0.5) Misses $(0.27) Estimate,2019-05-09 16:48:00-04:00,OMER,negative
954454.0,"Cantor Fitzgerald Initiates Coverage On Omeros Corporation - Common Stock with Overweight Rating, Announces $26 Price Target",2019-05-06 09:02:00-04:00,OMER,negative
954455.0,Omeros Corporation Announces Upcoming Educational Event At Annual Meeting Of The European Society Of Blood And Marrow Transplantation,2019-03-19 08:33:00-04:00,OMER,neutral
954456.0,Omeros shares are trading higher after the company beat Q4 EPS and sales estimates.,2019-03-01 09:17:00-05:00,OMER,positive
954457.0,"Omeros Q4 EPS $(0.48) Beats $(0.67) Estimate, Sales $22M Beat $16.08M Estimate",2019-03-01 07:31:00-05:00,OMER,neutral
954458.0,"Earnings Scheduled For March 1, 2019",2019-03-01 04:01:00-05:00,OMER,neutral
954459.0,"Omeros Reports United States Adopted Names Council, International Nonproprietary Names Expert Committee Selected Name For Co.'s OMS721 As 'Narsoplimab'",2019-02-20 08:38:00-05:00,OMER,positive
954460.0,71 Biggest Movers From Yesterday,2019-02-15 04:59:00-05:00,OMER,neutral
954461.0,52 Stocks Moving In Thursday's Mid-Day Session,2019-02-14 12:27:00-05:00,OMER,neutral
954462.0,Omeros Corporation Streamlines Path To Biologics License Application For OMS721 In HSCT-TMA Following Meeting With FDA,2019-02-14 08:37:00-05:00,OMER,neutral
954463.0,"Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data",2019-01-17 11:11:00-05:00,OMER,positive
954464.0,"Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy; Drug Appeared Well Tolerated With No Safety Concerns, Showed 61% Reduction In Proteinuria From Baseline",2019-01-17 08:16:00-05:00,OMER,positive
954465.0,55 Biggest Movers From Yesterday,2019-01-16 05:12:00-05:00,OMER,neutral
954466.0,56 Biggest Movers From Yesterday,2019-01-15 04:57:00-05:00,OMER,neutral
954467.0,41 Stocks Moving In Monday's Mid-Day Session,2019-01-14 13:04:00-05:00,OMER,neutral
954468.0,Omeros shares are trading higher after the company announced record high quarterly revenue in Q4.,2019-01-14 10:16:00-05:00,OMER,positive
954469.0,"Omeros Reports Prelim. Q4 Total, OMIDRIA Sales At ~$22M",2019-01-14 07:36:00-05:00,OMER,neutral
954470.0,Omeros Establishes Independent Academic Leadership Committee For OMS721 Phase 3 Clinical Program In IgA Nephropathy,2018-12-20 08:35:00-05:00,OMER,neutral
954471.0,Omeros Announces Research Collaboration With University Of Cambridge,2018-12-11 07:34:00-05:00,OMER,neutral
954472.0,UPDATE: Omeros Says 'EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review',2018-12-06 08:41:00-05:00,OMER,neutral
954473.0,Omeros Announces Submission Of Pediatric Investigational Plan For The Use Of OMS721 In Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy,2018-12-06 08:37:00-05:00,OMER,neutral
954474.0,85 Biggest Movers From Friday,2018-11-12 05:16:00-05:00,OMER,neutral
954475.0,Shares of Omeros Corp are trading down 22.3% after the company missed Q3 EPS estimates.,2018-11-09 14:14:00-05:00,OMER,neutral
954476.0,68 Stocks Moving In Friday's Mid-Day Session,2018-11-09 12:42:00-05:00,OMER,neutral
954477.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,OMER,neutral
954478.0,"Omeros Q3 EPS $(0.81) Misses $(0.71) Estimate, Sales $4.608M Beat $3.19M Estimate",2018-11-08 16:54:00-05:00,OMER,negative
954479.0,Omeros's OMS721 for Treatment of Hematopoietic Stem Cell Transplant is Granted Orphan Drug Designation by the FDA,2018-10-23 08:32:00-04:00,OMER,positive
954480.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,OMER,neutral
954481.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Oct. 2, 2018",2018-10-02 17:55:00-04:00,OMER,positive
954482.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-10-02 13:51:00-04:00,OMER,neutral
954483.0,24 Stocks Moving In Tuesday's Pre-Market Session,2018-10-02 08:05:00-04:00,OMER,neutral
954484.0,48 Biggest Movers From Yesterday,2018-10-02 04:51:00-04:00,OMER,neutral
954485.0,Omeros Shares Fall Over 40% On Renal Disease Trial Results,2018-10-01 16:37:00-04:00,OMER,positive
954486.0,"Omeros Shares Halted On Circuit Breaker; The Stock Has Been Halted Multiple Times Today, Turn On Benzinga Signals To Be Alerted To All Halts And Resumptions",2018-10-01 14:46:00-04:00,OMER,positive
954487.0,"Omeros Shares To Resume Trade At 2:45 p.m. ET, Down 5.1%",2018-10-01 14:41:00-04:00,OMER,positive
954488.0,"'So.. $OMER '721 IGA nephropathy study failed but the company said the data were positive…. in the headline of the press release. 

Sure…..' -Tweet From STAT News' Adam Feuerstein",2018-10-01 14:25:00-04:00,OMER,negative
954489.0,Omeros Corporation Announces Additional Data For OMS721 In IgA Nephropathy; Says Drug Was Well-Tolerated And No Safety Concerns Were Seen In Cohort Of Patients,2018-10-01 14:17:00-04:00,OMER,positive
954490.0,"Omeros Shares Halted, News Pending; Shares Down 5.1%",2018-10-01 14:11:00-04:00,OMER,positive
954491.0,Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA,2018-10-01 08:45:00-04:00,OMER,neutral
954492.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,OMER,neutral
954493.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,OMER,neutral
954494.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,OMER,neutral
954495.0,"Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More",2018-09-12 10:18:00-04:00,OMER,positive
954496.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,OMER,neutral
954497.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,OMER,neutral
954498.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,OMER,positive
954499.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,OMER,neutral
954500.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,OMER,neutral
954501.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,OMER,neutral
954502.0,55 Biggest Movers From Yesterday,2018-08-14 04:50:00-04:00,OMER,neutral
954503.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-13 12:36:00-04:00,OMER,neutral
954504.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-13 08:08:00-04:00,OMER,neutral
954505.0,61 Biggest Movers From Friday,2018-08-13 06:43:00-04:00,OMER,neutral
954506.0,60 Stocks Moving In Friday's Mid-Day Session,2018-08-10 13:27:00-04:00,OMER,neutral
954507.0,Omeros Corp. shares are trading 10% lower after the company announced lower-than-expected quarterly earnings per share and sales.,2018-08-10 11:27:00-04:00,OMER,positive
954508.0,"Omeros Q2 EPS $(0.70) Misses $(0.62) Estimate, Sales $1.655M Miss $2.12M Estimate",2018-08-09 16:26:00-04:00,OMER,negative
954509.0,Omeros Reports Patent Infringement Suit Against Sandoz Related To ANDA To Market Generic Version Of OMIDRIA Was Dismissed By Stipulation Of Parties,2018-07-26 09:13:00-04:00,OMER,negative
954510.0,Omeros Reports OMS721 Received European Orphan Drug Designation For Treatment In Hematoppoietic Stem Cell Transplantation,2018-07-25 08:32:00-04:00,OMER,neutral
954511.0,Omeros to Begin Selling OMIDRIA in Europe,2018-07-23 07:19:00-04:00,OMER,neutral
954512.0,"Omeros Starts Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction, Nicotine Addiction Planned as First Indication; Completion Of Trial Expected First Half Of 2019",2018-07-17 07:02:00-04:00,OMER,neutral
954513.0,"Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment, First Clinical Target for PDE7 Inhibitor to be Nicotine Addiction",2018-06-27 09:16:00-04:00,OMER,positive
954514.0,'$OMER says OMS721 deserves rapid approval for a deadly complication of bone marrow transplants b/c there are no approved treatments. But that's not true. An expert tells me $ALXN Soliris works very well',2018-05-31 07:54:00-04:00,OMER,positive
954515.0,Omeros Shares Quiet Premarket; STAT News' Adam Feuerstein Published Article 'Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws',2018-05-31 06:35:00-04:00,OMER,positive
954516.0,"Wedbush Maintains Neutral on Omeros, Raises Price Target to $20",2018-05-17 11:37:00-04:00,OMER,neutral
954517.0,41 Biggest Movers From Yesterday,2018-05-17 04:32:00-04:00,OMER,neutral
954518.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-05-16 12:39:00-04:00,OMER,neutral
954519.0,48 Biggest Movers From Yesterday,2018-05-15 04:26:00-04:00,OMER,neutral
954520.0,50 Biggest Movers From Friday,2018-05-14 05:07:00-04:00,OMER,neutral
954521.0,38 Stocks Moving In Friday's Mid-Day Session,2018-05-11 12:28:00-04:00,OMER,neutral
954522.0,"Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again",2018-05-11 08:21:00-04:00,OMER,negative
954523.0,"Omeros Q1 EPS $(0.62) Misses $(0.43) Estimate, Sales $1.588M Miss $6.89M Estimate",2018-05-10 17:25:00-04:00,OMER,negative
954524.0,Omeros Reports FDA Breakthrough Therapy Designation For OMS721 For Treatment Of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy,2018-04-26 14:15:00-04:00,OMER,neutral
954525.0,"Omeros Reports Results Of 4 Studies Evaluating OMIDRIA Presented At ASCRS, ASOA Meetings",2018-04-19 07:05:00-04:00,OMER,neutral
954526.0,"'Hey $OMER — Weren't we supposed to hear about breakthrough therapy status for OMS721 in HCT-TMA? 

But nice warrants.'-STAT's Adam Feuerstein Tweets",2018-04-11 09:36:00-04:00,OMER,positive
954527.0,41 Biggest Movers From Yesterday,2018-03-27 05:46:00-04:00,OMER,neutral
954528.0,"Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week",2018-03-26 12:33:00-04:00,OMER,positive
954529.0,42 Biggest Movers From Friday,2018-03-26 05:13:00-04:00,OMER,neutral
954530.0,30 Stocks Moving In Friday's Mid-Day Session,2018-03-23 13:10:00-04:00,OMER,neutral
954531.0,"Benzinga's Top Upgrades, Downgrades For March 23, 2018",2018-03-23 09:14:00-04:00,OMER,positive
954532.0,Wedbush Downgrades Omeros to Neutral,2018-03-23 07:25:00-04:00,OMER,neutral
954533.0,"ICYMI: GameStop, Omeros, Congress Impacts Biotechs",2018-03-23 06:56:00-04:00,OMER,neutral
954534.0,41 Biggest Movers From Yesterday,2018-03-23 04:52:00-04:00,OMER,neutral
954535.0,"Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim",2018-03-22 15:42:00-04:00,OMER,positive
954536.0,28 Stocks Moving In Thursday's Mid-Day Session,2018-03-22 12:47:00-04:00,OMER,neutral
954537.0,Mid-Day Market Update: Dow Falls Over 350 Points; Omeros Shares Spike Higher,2018-03-22 12:30:00-04:00,OMER,positive
954538.0,Biotech Winners And Losers From Congress' Latest Funding Bill,2018-03-22 11:46:00-04:00,OMER,negative
954539.0,"Benzinga Pro's Top 10 Most-Searched Tickers Thurs., Mar. 22",2018-03-22 09:54:00-04:00,OMER,positive
954540.0,Benzinga Pro's 5 Stocks To Watch Today,2018-03-22 08:39:00-04:00,OMER,neutral
954541.0,21 Stocks Moving In Thursday's Pre-Market Session,2018-03-22 08:24:00-04:00,OMER,neutral
954542.0,Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill,2018-03-22 08:07:00-04:00,OMER,positive
954543.0,Omeros Shares Up Nearly 30% Thurs. Following Favorable Determination In Latest Spending Package: 'an extra two years of charging Medicare higher prices for its cataract surgery drug',2018-03-22 07:26:00-04:00,OMER,positive
954544.0,32 Stocks Moving In Friday's Mid-Day Session,2018-03-02 12:20:00-05:00,OMER,neutral
954545.0,30 Stocks Moving In Friday's Pre-Market Session,2018-03-02 08:09:00-05:00,OMER,neutral
954546.0,"Omeros Reports Q4 EPS $(0.34) vs $(0.14) Est., Sales $13.8M vs $23M Est.",2018-03-01 16:56:00-05:00,OMER,neutral
954547.0,"Adam Feuerstein Tweet: $OMER, in its PR, basically admits Omidria sales have completely dried up in Q1 due to loss of pass-through status.",2018-03-01 16:09:00-05:00,OMER,neutral
954548.0,Omeros Receives EU Orphan Drug Designation For OMS721,2018-02-27 13:48:00-05:00,OMER,neutral
954549.0,56 Biggest Movers From Yesterday,2018-02-23 05:17:00-05:00,OMER,neutral
954550.0,"Adam Feuerstein Tweets: Here's the thing, Bill. $OMER doesn't have multiple ph3 drugs. They have a single drug in a ph3 that isn't enrolling after more than a year, and a promise to start another ph3 based on data from 4 patients. Not great.",2018-02-22 11:49:00-05:00,OMER,negative
954551.0,"Adam Feuerstein Tweets: $OMER says nothing about Omidria sales cliff. Instead, pivots to touring a scientifically absurd OS analysis from a tiny, OMS721 single arm clinical trial.",2018-02-15 08:00:00-05:00,OMER,neutral
954552.0,UPDATE: Omeros Highlights 'Greater than 16-Fold Improvement in Survival Compared to Historical Control',2018-02-15 07:42:00-05:00,OMER,positive
954553.0,Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy,2018-02-15 07:42:00-05:00,OMER,positive
954554.0,42 Biggest Movers From Yesterday,2018-02-15 04:43:00-05:00,OMER,neutral
954555.0,36 Stocks Moving In Wednesday's Mid-Day Session,2018-02-14 12:52:00-05:00,OMER,neutral
954556.0,Adam Feuerstein Tweets: $OMER -17% on the highly critical report from FourWorld Capital. It's an informative read. Recommend. fourworldcapital.com/omer-download,2018-02-14 12:19:00-05:00,OMER,neutral
954557.0,Omeros' OMS721 for Tratement of IgA Nephropathy Gets a Positive Opinion from the European Medicines Agency,2018-01-22 07:00:00-05:00,OMER,positive
954558.0,Stat News Reporter Adam Feuerstein Tweets: $OMER OMS721 update in-line w/ expectations but what's the real status of the ph3 aHUS study? Any patients actually enrolled? Any timeline for completion? $OMER doesn't like pesky questions.,2018-01-03 07:08:00-05:00,OMER,negative
954559.0,"Omeros Reaches Agreement With FDA On Protocol For Its Phase 3 Trial Evaluating OMS721, Patient Enrollment To Begin Early Next Month",2018-01-03 07:02:00-05:00,OMER,positive
954560.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-12 12:33:00-05:00,OMER,neutral
954561.0,Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use,2017-12-12 10:12:00-05:00,OMER,negative
954562.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-12-12 08:09:00-05:00,OMER,neutral
954563.0,Omeros Corporation Announces FDA Approval of OMIDRIA for Use in Pediatric Patients,2017-12-12 07:06:00-05:00,OMER,positive
954564.0,Omeros Reports FDA Approval Of OMIDRIA For Use In Pediatric Patients,2017-12-12 07:00:00-05:00,OMER,positive
954565.0,32 Stocks Moving In Monday's Pre-Market Session,2017-11-27 08:03:00-05:00,OMER,neutral
954566.0,44 Biggest Movers From Friday,2017-11-13 05:41:00-05:00,OMER,neutral
954567.0,Mid-Afternoon Market Update: Esterline Drops Following Downbeat Q4 Results; Alteryx Shares Jump,2017-11-10 14:37:00-05:00,OMER,positive
954568.0,35 Stocks Moving In Friday's Mid-Day Session,2017-11-10 12:41:00-05:00,OMER,neutral
954569.0,Mid-Day Market Update: Omeros Climbs After Strong Q3 Results; LightPath Technologies Shares Plunge,2017-11-10 12:00:00-05:00,OMER,positive
954570.0,Can Omeros Top-Line Growth Continue?,2017-11-10 11:36:00-05:00,OMER,positive
954571.0,Mid-Morning Market Update: Markets Open Lower; J C Penney Sales Beat Estimates,2017-11-10 10:10:00-05:00,OMER,negative
954572.0,31 Stocks Moving In Friday's Pre-Market Session,2017-11-10 08:19:00-05:00,OMER,neutral
954573.0,Omeros Reports Q3 EPS $(0.16) vs $(0.33) Est.,2017-11-09 16:03:00-05:00,OMER,neutral
954574.0,"Benzinga's Top Upgrades, Downgrades For November 8, 2017",2017-11-08 09:28:00-05:00,OMER,positive
954575.0,"H.C. Wainwright Initiates Coverage On Omeros with Buy Rating, Announces $30.00 Price Target",2017-11-08 07:28:00-05:00,OMER,neutral
954576.0,"Omeros Option Alert: Jan, 2019 $17 Calls at the Ask: 1500 @ $4.0 vs 48 OI; Ref=$13.8",2017-11-06 11:35:00-05:00,OMER,positive
954577.0,"Omeros Option Alert: Jan, 2019 $17 Calls at the Ask: 1000 @ $4.0 vs 48 OI; Ref=$13.85",2017-11-06 11:18:00-05:00,OMER,positive
954578.0,Omeros Reports Extended Follow-Up Data From Patients With IgA Nephropathy Treated With OMS721 Presented At ASN Nov. 4,2017-11-06 07:35:00-05:00,OMER,neutral
954579.0,"Adam Feuerstein Tweets: $OMER Omidria losing Medicare pass-through code, so price will fall a lot. Funny, this is one of risks shorts warned about ahead of time.",2017-11-02 13:14:00-04:00,OMER,negative
954580.0,Cowen & Co. Downgrades Omeros to Market Perform,2017-11-02 12:53:00-04:00,OMER,neutral
954581.0,Hearing Cowen Downgrades Omeros From Outperform To Market Perform,2017-11-02 12:51:00-04:00,OMER,neutral
954582.0,"Omeros Shares Continue Higher Mon., Up 9.4%, Following 12% Rally On Fri. Amid News Of 'Substantial, Significant' Improvements In TMA Activity During Phase 2 Trial Of OMS721",2017-10-30 10:38:00-04:00,OMER,positive
954583.0,"Omeros Reports Substantial, Significant Improvement Markers of TMA Activity Were Seen In Expanded Number Of Study Patients In Phase 2 OMS721 Trial, Prepares To Begin Phase 3 Clinical Trial",2017-10-26 11:32:00-04:00,OMER,positive
954584.0,40 Biggest Movers From Yesterday,2017-10-25 05:31:00-04:00,OMER,neutral
954585.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Polaris Shares Surge On Upbeat Earnings,2017-10-24 14:32:00-04:00,OMER,negative
954586.0,Mid-Day Market Update: Dow Rises 175 Points; Identiv Shares Plunge,2017-10-24 12:09:00-04:00,OMER,positive
954587.0,Mid-Morning Market Update: Markets Open Higher; General Motors Profit Tops Expectations,2017-10-24 10:05:00-04:00,OMER,positive
954588.0,STAT News Adam Feuerstein '$OMER presented a patient anecdote instead of real clinical trial data at a medical meeting. Still won't answer questions.',2017-10-20 07:52:00-04:00,OMER,neutral
954589.0,UPDATE: Omeros Says Results From OMS721 Trial 'May Expand Target for Omeros' Planned Phase 3 Program in HCT-TMA',2017-10-20 07:09:00-04:00,OMER,positive
954590.0,Omeros Reports Successful OMS721 Treatment Of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy And Graft-Versus-Host Disease,2017-10-20 07:08:00-04:00,OMER,positive
954591.0,Omeros Reports Settlement Of Infringement Suit Against Par,2017-10-05 11:01:00-04:00,OMER,negative
954592.0,Benzinga's Option Alert Recap From August 31,2017-08-31 16:22:00-04:00,OMER,positive
954593.0,Omeros Spikes to High of $20.76 on Volume,2017-08-31 10:35:00-04:00,OMER,neutral
954594.0,Omeros Option Alert: Sep 15 $23 Puts Sweep (30) at the Bid: 603 @ $2.952 vs 171 OI; Ref=$20.26,2017-08-31 10:32:00-04:00,OMER,positive
954595.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-08-24 08:12:00-04:00,OMER,neutral
954596.0,"STAT News' Adam Feuerstein Tweets '$OMER defends its drug, but still won't answer basic questions'",2017-08-23 13:07:00-04:00,OMER,neutral
954597.0,"STAT News' Adam Feuerstein Tweets '$OMER doesn't answer same questions when asked by analysts or institutional investors. Strange, eh?'",2017-08-22 10:48:00-04:00,OMER,negative
954598.0,18 Biggest Mid-Day Losers For Tuesday,2017-08-15 13:31:00-04:00,OMER,negative
954599.0,Omeros Prices 3M Shares At $22.75/Share,2017-08-15 09:18:00-04:00,OMER,positive
954600.0,"Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet",2017-08-15 08:40:00-04:00,OMER,neutral
954601.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-08-15 08:24:00-04:00,OMER,neutral
954602.0,Omeros Announces 3M Share Offering Common Stock,2017-08-14 16:42:00-04:00,OMER,positive
954603.0,Omeros Reports Data On Patients With IgA Nephropathy Treated With OMS721: 'Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data',2017-08-14 12:58:00-04:00,OMER,positive
954604.0,"Omeros Reports Q2 GAAP EPS $(0.33) vs $(0.32) In Same Qtr. Last Year, Sales $17.2M",2017-08-08 17:57:00-04:00,OMER,neutral
954605.0,"FDA Grants Orphan Drug Designation to Omeros' OMS721, Initiating Phase 3 Program for OMS721 in IgA Nephropathy with Both Breakthrough and Orphan Designations",2017-08-04 11:11:00-04:00,OMER,positive
954606.0,Watch These 5 Huge Put Purchases In Monday Trade,2017-07-10 04:21:00-04:00,OMER,positive
954607.0,Benzinga's Option Alert Recap From July 7,2017-07-07 16:20:00-04:00,OMER,positive
954608.0,Option Alert: Omeros Nov 12.0 Puts Sweep: 667 @  ASK  $0.80: 700 traded vs 133 OI:  Earnings 8/9 After Close (est)  $18.97 Ref,2017-07-07 11:30:00-04:00,OMER,positive
954609.0,UPDATE: Omeros On Art Doyle Report: 'The report is actionable and the company is pursuing legal remedies. Omeros intends to hold all responsible parties accountable',2017-06-29 07:08:00-04:00,OMER,positive
954610.0,"UPDATE: Omeros On Art Doyle Report: 'This report is replete with falsehoods, misleading statements and incorrect analyses and conclusions'",2017-06-29 07:07:00-04:00,OMER,negative
954611.0,Omeros Offers Statement Following Recent False Report,2017-06-29 07:07:00-04:00,OMER,neutral
954612.0,"Omeros Shares Fall Just After Open, Now Down 1.8% As Traders Circulating Tuesday Short Report From Art Doyle As If It Is New Today; Stock Now Bouncing Off Session Lows",2017-06-28 09:56:00-04:00,OMER,positive
954613.0,Mid-Afternoon Market Update: Portola Climbs On FDA Approval For Bevyxxa; American Software Shares Plunge,2017-06-23 14:30:00-04:00,OMER,positive
954614.0,Martin Shkreli In Facebook Post On Omeros Says: 'Take profits $OMER and don't forget to say thank you',2017-06-23 10:40:00-04:00,OMER,positive
954615.0,8K Filing From Omeros Shows Co. Files Patent Infringement Suit Against Sandoz,2017-06-22 17:27:00-04:00,OMER,negative
954617.0,2 Longs And 2 Shorts To Watch,2017-06-14 14:09:00-04:00,OMER,neutral
954619.0,Cantor Fitzgerald's Piros Still Isn't A Buyer Of Omeros After Tuesday's FDA Win,2017-06-13 13:20:00-04:00,OMER,positive
954620.0,Omeros Reports FDA Granted Breakthrough Designation For OMS721 For Treatment Of IgA Nephropathy,2017-06-13 11:30:00-04:00,OMER,positive
954622.0,15 Biggest Mid-Day Gainers For Wednesday,2017-05-17 12:31:00-04:00,OMER,neutral
954623.0,Omeros Completes Phase 2 Trial,2017-05-17 07:09:00-04:00,OMER,neutral
954624.0,"Cantor Fitzgerald Downgrades Omeros To Neutral, Lowers Price Target To $15",2017-05-11 09:18:00-04:00,OMER,negative
954625.0,"Omeros Reports Q1 EPS $(0.34) vs $(0.35) Est., Sales $12.257M vs $13.32M Est.",2017-05-10 16:35:00-04:00,OMER,neutral
954626.0,The Latest Top Hot Short Ideas: Sears And Credit Acceptance,2017-04-04 15:24:00-04:00,OMER,positive
954627.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-30 12:39:00-04:00,OMER,neutral
954628.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-03-30 08:21:00-04:00,OMER,neutral
954629.0,UPDATE: Omeros Reports New Data 'corroborate and expand on trial results reported in Q4'16',2017-03-30 07:03:00-04:00,OMER,positive
954630.0,Omeros Reports Data in OMS721 Phase 2 Trial in Renal Diseases,2017-03-30 07:02:00-04:00,OMER,neutral
954631.0,20 Biggest Mid-Day Gainers For Tuesday,2017-03-28 12:42:00-04:00,OMER,neutral
954632.0,Omeros Rallies After OMS721 Presentation,2017-03-28 12:14:00-04:00,OMER,neutral
954633.0,12 Biggest Mid-Day Gainers For Monday,2017-03-20 12:38:00-04:00,OMER,neutral
954634.0,Omeros Pops to High of $11.86 on Volume,2017-03-20 10:25:00-04:00,OMER,neutral
954635.0,"Omeros Reports Q4 EPS $(0.45) vs $(0.56) Est., Sales $12.9M vs $12.5M Est.",2017-03-16 16:10:00-04:00,OMER,neutral
954636.0,"Earnings Scheduled For March 16, 2017",2017-03-16 04:05:00-04:00,OMER,neutral
954637.0,Omeros Shorts Are Feeling The Heat,2017-02-09 12:07:00-05:00,OMER,positive
954638.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,OMER,neutral
954639.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,OMER,neutral
954640.0,Data from Omeros' OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference,2016-12-07 07:01:00-05:00,OMER,neutral
954641.0,Omeros Wins EUR 1.3M Grant to Study the Role of MASP-2 and Lectin Pathway in Trauatic Brain Injury,2016-11-30 07:31:00-05:00,OMER,positive
954642.0,Omeros Announces Outcome of OMIDRIA Pediatric Cataract Trial,2016-11-21 07:00:00-05:00,OMER,neutral
954643.0,18 Biggest Mid-Day Gainers For Thursday,2016-11-10 13:09:00-05:00,OMER,neutral
954644.0,Mid-Day Market Update: NASDAQ Down Over 1%; TubeMogul Shares Surge Following Acquisition News,2016-11-10 12:10:00-05:00,OMER,positive
954645.0,"Omeros Up 18+% After Positive Results in MASP-3 Inhibitor OMS906 Study, Showed Sustained Ablation of APC Activity for ~16 Days; Preparing for Clinical Trials",2016-11-10 10:36:00-05:00,OMER,positive
954646.0,Mid-Morning Market Update: Markets Open Higher; Ralph Lauren Profit Tops Views,2016-11-10 10:05:00-05:00,OMER,positive
954647.0,20 Stocks Moving In Thursday's Pre-Market Session,2016-11-10 08:28:00-05:00,OMER,neutral
954648.0,Omeros Corp. Reports Q3 EPS $(0.34) vs $(0.40) Est.,2016-11-09 17:21:00-05:00,OMER,neutral
954649.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-09 08:28:00-05:00,OMER,neutral
954650.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-11-09 06:04:00-05:00,OMER,neutral
954651.0,22 Stocks Moving In Tuesday's Pre-Market Session,2016-11-08 08:34:00-05:00,OMER,neutral
954652.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-07 08:34:00-05:00,OMER,neutral
954653.0,Technical Alert: Omeros Corporation Higher For Fourth Day In A Row,2016-11-04 13:31:00-04:00,OMER,positive
954654.0,22 Stocks Moving In Friday's Pre-Market Session,2016-11-04 08:36:00-04:00,OMER,neutral
954655.0,20 Biggest Mid-Day Gainers For Thursday,2016-11-03 12:34:00-04:00,OMER,neutral
954656.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-11-03 08:38:00-04:00,OMER,neutral
954657.0,Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy,2016-11-03 07:45:00-04:00,OMER,neutral
954658.0,22 Biggest Mid-Day Gainers For Wednesday,2016-11-02 12:50:00-04:00,OMER,neutral
954659.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-11-02 08:43:00-04:00,OMER,neutral
954660.0,Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone,2016-11-02 07:06:00-04:00,OMER,positive
954661.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-11-01 08:32:00-04:00,OMER,neutral
954662.0,15 Biggest Mid-Day Gainers For Monday,2016-10-31 12:47:00-04:00,OMER,neutral
954663.0,16 Stocks Moving In Monday's Pre-Market Session,2016-10-31 08:30:00-04:00,OMER,neutral
954664.0,Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy,2016-10-31 07:05:00-04:00,OMER,neutral
954665.0,Omeros Earlier Announced $125 Million New Credit Facility,2016-10-27 07:47:00-04:00,OMER,positive
954666.0,10 Stocks Which Rallied Three Days On Increasing Volume,2016-10-24 07:02:00-04:00,OMER,neutral
954667.0,Omeros Stock Remains Higher On Promising Kidney Drug Trial Data,2016-10-20 14:43:00-04:00,OMER,positive
954668.0,Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher,2016-10-20 12:15:00-04:00,OMER,positive
954669.0,Omeros Finds Buyers In The $7 Handle Again,2016-10-20 12:01:00-04:00,OMER,neutral
954670.0,UPDATE: Omeros Says No Significant Safety Concerns Have Been Observed,2016-10-20 10:23:00-04:00,OMER,positive
954671.0,Omeros Reports Data from OMS721 Phase 2 Trial Showed 'Targeted Indications for the Company's MASP-2 Inhibitor Continue to Expand',2016-10-20 10:22:00-04:00,OMER,positive
954672.0,16 Stocks Moving In Wednesday's Pre-Market Session,2016-10-19 08:20:00-04:00,OMER,neutral
954673.0,Omeros Calls New Phase 2 Data For PPAR Positive,2016-10-19 07:06:00-04:00,OMER,positive
954674.0,15 Biggest Mid-Day Gainers For Monday,2016-10-17 12:51:00-04:00,OMER,neutral
954675.0,Selling The News In Omeros,2016-10-17 10:27:00-04:00,OMER,neutral
954676.0,Mid-Morning Market Update: Markets Edge Lower; Bank of America Profit Tops Views,2016-10-17 10:14:00-04:00,OMER,positive
954677.0,Omeros Stock Lifted By Positive Phase 2 Clinical Data,2016-10-17 08:58:00-04:00,OMER,positive
954678.0,18 Stocks Moving In Monday's Pre-Market Session,2016-10-17 08:46:00-04:00,OMER,neutral
954679.0,Omeros +8.7% Premarket at $7.98; Co Announced Positive Data from Phase 2 Trial for Treatment of Kidney Disorders,2016-10-17 07:25:00-04:00,OMER,positive
954680.0,Mid-Day Market Update: Advanced Micro Devices Climbs After Chip Deal With Alibaba; Ocean Power Technologies Shares Slide,2016-10-14 12:20:00-04:00,OMER,positive
954681.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; VOXX Shares Spike Higher,2016-10-12 15:13:00-04:00,OMER,negative
954682.0,7 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-06 07:02:00-04:00,OMER,neutral
954683.0,10 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-05 08:20:00-04:00,OMER,neutral
954684.0,20 Biggest Mid-Day Losers For Thursday,2016-08-11 13:32:00-04:00,OMER,negative
954685.0,22 Stocks Moving In Thursday's Pre-Market Session,2016-08-11 08:24:00-04:00,OMER,neutral
954686.0,Omeros Announces Public Offering of Common Stock $40M,2016-08-10 16:03:00-04:00,OMER,neutral
954687.0,Omeros Reports OMS906 Showed Efficacy in Paroxysmal Nocturnal Hemoblobinuria Model,2016-08-10 07:05:00-04:00,OMER,neutral
954688.0,"Omeros Corp. Reports Q2 EPS $(0.32) vs. Est. $(0.50), Rev. $10M vs. Est. $9.24M",2016-08-09 16:43:00-04:00,OMER,neutral
954689.0,Omeros Reports Closing of Patient Enrollment in Pediatric Trial of OMIDRIA,2016-06-29 07:06:00-04:00,OMER,neutral
954690.0,"Cantor Fitzgerald Starts Omeros With Buy, $21PT",2016-06-03 09:56:00-04:00,OMER,neutral
954691.0,"Cantor Fitzgerald Initiates Coverage on Omeros at Buy, Announces $21.00 PT",2016-06-02 16:19:00-04:00,OMER,neutral
954692.0,Omeros Sells off to Low of $18.20 on Vol,2016-05-23 12:01:00-04:00,OMER,negative
954693.0,Mid-Day Market Update: Sodastream Gains Following Earnings Beat; NewLink Genetics Shares Decline,2016-05-10 12:14:00-04:00,OMER,positive
954694.0,Mid-Morning Market Update: Markets Open Higher; Allergan Earnings Top Views,2016-05-10 10:10:00-04:00,OMER,positive
954695.0,"Omeros Reports Q1 EPS $(0.54) vs $(0.43) Est., Sales $7.4M vs $8.8M Est.",2016-05-10 07:22:00-04:00,OMER,neutral
954696.0,Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA,2016-05-10 07:20:00-04:00,OMER,positive
954697.0,Omeros Announces Exclusive Middle East Distribution Agreement for OMIDRIA,2016-05-10 07:11:00-04:00,OMER,positive
954698.0,Omeros Reports Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases,2016-04-20 07:07:00-04:00,OMER,neutral
954699.0,"Roth Capital Terminates Buy Rating on Omeros, Removes $38.00 PT",2016-04-12 05:59:00-04:00,OMER,neutral
954700.0,Benzinga's Volume Movers,2016-03-08 10:19:00-05:00,OMER,neutral
954701.0,"Omeros Reports Initiation of Phase 3 Program for OMS721 in aHUS Following FDA Meeting, Says Single Pivotal Study Needed for Phase 3",2016-03-08 07:02:00-05:00,OMER,neutral
954702.0,"Earnings Scheduled For March 8, 2016",2016-03-08 04:09:00-05:00,OMER,neutral
954703.0,"Omeros Corp Reports Q4 EPS $(0.52) Vs Est $(0.55), Sales $6.675M Vs Est $5.35M",2016-03-07 17:23:00-05:00,OMER,neutral
954704.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,OMER,neutral
954705.0,Omeros Spikes Higher,2015-12-18 15:52:00-05:00,OMER,neutral
954706.0,9 IPOs That Fell Flat On Wall Street,2015-11-19 15:05:00-05:00,OMER,neutral
954707.0,"Omeros Reports Q3 EPS ($0.53) Vs Est ($0.47), Sales $3.26M Vs Est $7.20M",2015-11-09 16:55:00-05:00,OMER,neutral
954708.0,Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®,2015-10-15 07:02:00-04:00,OMER,positive
954709.0,Omeros Files Infringement Suits Against Par,2015-09-03 09:15:00-04:00,OMER,negative
954710.0,Omeros Recevies Patent for Use of PDE7 Inhibitors for Treatment of Movement  Disorders,2015-09-01 11:03:00-04:00,OMER,negative
954711.0,Where Is Omeros Corporation Now?,2015-08-26 14:55:00-04:00,OMER,neutral
954712.0,Omeros Corporation: Another Biotech Bubble In The Making?,2015-08-18 14:19:00-04:00,OMER,neutral
954713.0,Mid-Day Market Update: Tuesday's Top 10 Volume Stocks,2015-08-18 12:59:00-04:00,OMER,positive
954714.0,Mid-Day Market Update: National Penn Bancshares Surges On Acquisition News; Vera Bradley Shares Slide,2015-08-18 12:47:00-04:00,OMER,positive
954715.0,"Mid-Day Market Update: Tuesday's Movers, China's Growth Worries And More",2015-08-18 11:59:00-04:00,OMER,negative
954716.0,Mid-Morning Market Update: Markets Open Lower; Wal-Mart Lowers Full-Year Forecast,2015-08-18 10:32:00-04:00,OMER,negative
954717.0,Benzinga's Volume Movers,2015-08-18 10:31:00-04:00,OMER,neutral
954718.0,Morning Market Gainers,2015-08-18 09:38:00-04:00,OMER,neutral
954719.0,UPDATE: Omeros +68% Premarket Following Announcement of Additional Positive Data in OMS721 Phase 2 Clinical Trial,2015-08-18 08:38:00-04:00,OMER,positive
954720.0,Benzinga's Top #PreMarket Gainers,2015-08-18 08:15:00-04:00,OMER,positive
954721.0,Omeros +22% Premarket Following Announcement of Additional Positive Data in OMS721 Phase 2 Clinical Trial,2015-08-18 08:08:00-04:00,OMER,positive
954722.0,UPDATE: Omeros Provides Phase 2 Study Update,2015-08-18 07:05:00-04:00,OMER,neutral
954723.0,Omeros Provides Phase 2 Study Update,2015-08-18 07:04:00-04:00,OMER,neutral
954724.0,Omeros Announces Plans to file Patent Suit Against Par Pharma,2015-08-17 07:01:00-04:00,OMER,neutral
954725.0,"Omeros Corp. Reports Q2 EPS $(0.44) vs. Est. $(0.56), Rev. $3.2M vs. Est. $2.86M",2015-08-10 16:11:00-04:00,OMER,neutral
954726.0,Benzinga's Top Initiations,2015-08-10 10:00:00-04:00,OMER,positive
954727.0,"Roth Capital Initiates Coverage on Omeros at Buy, Announces $38.00 PT",2015-08-10 07:26:00-04:00,OMER,neutral
954728.0,Omeros Announces FDA Grants Fast Track Designation to Complement Inhibitor OMS721 for aHUS,2015-07-23 07:09:00-04:00,OMER,positive
954729.0,"Watch Shares of Omeros Here as Wedbush's Liana Moussatos Saying Buy the Dip Given 'Potential 2015 Catalysts,' Outperform Rating, $61 Price Target Reiterated",2015-07-02 15:23:00-04:00,OMER,positive
954730.0,Omeros Corp. Enters Licensing Agreement With Affiliates Of Fagron NV Product OMS103,2015-06-16 07:01:00-04:00,OMER,positive
954731.0,Omidria Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use,2015-05-22 07:01:00-04:00,OMER,positive
954732.0,"Omeros Reports Q1 Loss $0.51 Vs Est Loss $0.63, Sales $388K",2015-05-11 16:45:00-04:00,OMER,negative
954733.0,Omeros Announces European Regulatory Authority Approves Compassionate Use for OMS721,2015-04-14 07:07:00-04:00,OMER,positive
954734.0,Omeros Corp. Launches Omidria In U.S.,2015-04-02 07:02:00-04:00,OMER,neutral
954735.0,UPDATE: Omeros Beats Q4 Estimates,2015-03-16 17:41:00-04:00,OMER,neutral
954736.0,"Omeros Corp. Reports Q4 EPS $(0.61) vs. Est. $(0.62), Rev. $180K Vs. Est $90K",2015-03-16 16:07:00-04:00,OMER,neutral
954737.0,"Earnings Scheduled For March 16, 2015",2015-03-16 04:34:00-04:00,OMER,neutral
954738.0,Benzinga's Volume Movers,2015-03-02 10:39:00-05:00,OMER,neutral
954739.0,Omeros Corporation Announces Phase 2 OMS721 Trial Results in Extended Access for Compassionate Use,2015-02-19 07:08:00-05:00,OMER,positive
954740.0,Omeros Closes $84M Public Offering,2015-02-03 17:02:00-05:00,OMER,neutral
954741.0,Omeros Prices $75M Public Offering of Common Stock and Pre-Funded Warrants,2015-01-29 08:34:00-05:00,OMER,neutral
954742.0,"Omeros Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants",2015-01-28 16:11:00-05:00,OMER,neutral
954743.0,Omeros Files for Potential Stock Offering; Size Not Disclosed,2015-01-28 16:10:00-05:00,OMER,neutral
954744.0,Filing from Omeros Shows Registration for Automatic Mixed Securities Shelf Offering,2015-01-16 17:11:00-05:00,OMER,positive
954745.0,Omeros Reports OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients,2014-11-19 07:21:00-05:00,OMER,negative
954746.0,"Mid-Day Market Update: SunEdison, TerraForm Jump On First Wind Acquisition; TJX Shares Drop",2014-11-18 13:17:00-05:00,OMER,neutral
954747.0,The Top 25 Analysts On Wall Street,2014-11-13 10:47:00-05:00,OMER,positive
954748.0,"US Stock Futures Edge Lower Ahead Of Earnings, Jobless Claims ",2014-11-06 07:47:00-05:00,OMER,negative
954749.0,Omeros Announces Positive Data For MASP-2 Inhibitor In Experimental Model Of Stroke,2014-11-06 07:05:00-05:00,OMER,positive
954750.0,Omeros Corporation Announces It Has Received Transitional Pass-through Status For Omidria ,2014-10-30 07:18:00-04:00,OMER,neutral
954751.0,Morning Market Losers ,2014-10-21 10:07:00-04:00,OMER,negative
954752.0,Benzinga's Top #PreMarket Losers,2014-10-21 08:21:00-04:00,OMER,negative
954753.0,Omeros Provides Update on PDE10 Inhibitor Program ,2014-10-21 07:18:00-04:00,OMER,negative
954754.0,Omeros Corporation Reports Q2 EPS of $(0.53) Which May Not Compare $(0.52) Est,2014-08-11 16:04:00-04:00,OMER,neutral
954755.0,Morning Market Movers ,2014-06-02 09:40:00-04:00,OMER,neutral
954756.0,Omeros Shares Resume Trading Up 11% Following Report of FDA Approval of Omidria,2014-06-02 08:18:00-04:00,OMER,positive
954757.0,Benzinga's Top #PreMarket Gainers,2014-06-02 08:10:00-04:00,OMER,positive
954758.0, Omeros Receives FDA Approval of Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures,2014-06-02 07:02:00-04:00,OMER,positive
954759.0,"Form 8-K from Omeros Shows Pact with Inventiv, Co. Will Pay Inventiv Fees",2014-05-22 17:04:00-04:00,OMER,negative
954760.0,Omeros Corporation Reports Q1 EPS of $(0.54) vs $(0.45) Est,2014-05-12 16:21:00-04:00,OMER,neutral
954761.0,US Stock Futures Edge Higher Ahead Of Jobless Claims Data,2014-04-03 07:34:00-04:00,OMER,neutral
954762.0,Omeros Announces IND Cleared by FDA for OMS721 in Thrombotic Microangiopathies ,2014-04-03 07:12:00-04:00,OMER,positive
954763.0,Omeros to Make Presentatiom on OMS824 Phase 2 Clinical Program at Schizophrenia International Research Conference ,2014-04-01 07:09:00-04:00,OMER,neutral
954764.0,Omeros Prices 3M Shares at $11.50/Share,2014-03-14 08:34:00-04:00,OMER,positive
954765.0,Omeros Announces Offering of Common Shares,2014-03-13 16:37:00-04:00,OMER,positive
954766.0,Omeros Announces Proposed Public Offering of Common Stock,2014-03-13 16:37:00-04:00,OMER,neutral
954767.0,Omeros Corporation Reports Q4 EPS of $(0.46) vs $(0.38) Est,2014-03-13 16:18:00-04:00,OMER,neutral
954768.0,Omeros Reports Positive OMS721 Data in Serum from Patients with aHUS ,2014-03-10 07:03:00-04:00,OMER,positive
954769.0,Omeros Announces Additional Positive Data from OMS824 Phase 2a Schizophrenia Clinical Trial ,2014-03-06 07:10:00-05:00,OMER,positive
954770.0,Omeros Submits IND to FDA for Advance OMS721 Phase 2 Clinical Program ,2014-03-04 07:07:00-05:00,OMER,neutral
954771.0,"McNicoll Lewis Vlak Maintains Buy on Omeros Corporation, Raises PT to $19.00",2014-02-11 07:59:00-05:00,OMER,neutral
954772.0,Benzinga's Top #PreMarket Gainers,2014-02-05 08:06:00-05:00,OMER,positive
954773.0,Omeros Receives FDA Fast Track Designation for  OMS824 Huntington's Disease Program ,2014-02-05 07:54:00-05:00,OMER,neutral
954774.0,Omeros Announces Positive Data for Phase 1 Clinical Trial with OMS721 ,2014-02-03 07:04:00-05:00,OMER,positive
954775.0,UPDATE: Omeros Announces Positive OMS824 Phase 2a Clinical Trial Results,2014-01-29 07:07:00-05:00,OMER,positive
954776.0,Omeros Reports Positive Results From OMS824 Phase 2a Clinical Trial,2014-01-29 07:04:00-05:00,OMER,positive
954777.0,Benzinga's Top #PreMarket Gainers,2013-12-18 08:36:00-05:00,OMER,positive
954778.0,UPDATE: FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies ,2013-12-18 07:06:00-05:00,OMER,positive
954779.0,Hearing Wedbush Names Omeros Top Pick for 2014; $32 PT,2013-12-16 09:45:00-05:00,OMER,positive
954780.0,Omeros Announces FDA Accepts Omidria as Brand Name for OMS302 ,2013-11-20 07:01:00-05:00,OMER,positive
954781.0,Omeros Presents Phase 3 OMS302 Clinical Data Annual American Academy of Ophthalmology Meeting ,2013-11-19 07:04:00-05:00,OMER,neutral
954782.0,Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration,2013-11-05 07:13:00-05:00,OMER,positive
954783.0,Omeros Reports Positive OMS721 Data,2013-11-05 07:06:00-05:00,OMER,positive
954784.0,Omeros Says FDA Has Agreed to Pediatric Study Plan for OMS302,2013-10-15 07:01:00-04:00,OMER,positive
954785.0,Benzinga's Top Pre-Market Gainers,2013-10-03 08:12:00-04:00,OMER,positive
954786.0,Omeros Identifies Six Additional Class A Orphan GPCRs ,2013-10-03 07:02:00-04:00,OMER,neutral
954787.0,"Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price",2013-10-02 12:09:00-04:00,OMER,positive
954788.0,Omeros Spikes Higher; May be Attributed to Wedbush Raising PT to $32,2013-10-02 10:39:00-04:00,OMER,neutral
954789.0,"FDA, EMA Accept OMS302 Marketing Applications  for Review ",2013-10-02 07:03:00-04:00,OMER,positive
954790.0,Omeros Announces FDA Orphan Drug Designation for OMS824 for Huntington's Disease ,2013-09-30 07:05:00-04:00,OMER,neutral
954791.0,Bloomberg Reporting Omeros Wins Orphan Drug Designation for Huntington's Disease Treatment,2013-09-27 11:03:00-04:00,OMER,positive
954792.0,Omeros Initiates Phase 2 Clinical Trial with OMS824 ,2013-09-19 07:01:00-04:00,OMER,neutral
954793.0,Benzinga's Top Pre-Market Losers,2013-09-17 08:17:00-04:00,OMER,negative
954794.0,Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use,2013-09-16 12:18:00-04:00,OMER,positive
954795.0,"Shares of Omeros Rocket Higher (43%), Wedbush's Moussatos Says OMS302 Could Benefit from FDA Restrictions on Topical Solutions in Intraocular Lens Replacement Surgery, Boosted Target from $18 to $28, Outperform Maintained",2013-09-16 10:31:00-04:00,OMER,positive
954796.0,Morning Market Movers ,2013-09-16 10:21:00-04:00,OMER,neutral
954797.0,Omeros Reports Additional Positive Results from Phase 1 OMS824 Clinical Trial,2013-09-12 07:02:00-04:00,OMER,positive
954798.0,"Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer ",2013-08-13 07:08:00-04:00,OMER,neutral
954799.0,Shares of Omeros Bounce Over $5.40 Following Mid-Day Comments from MLV's Zavoico,2013-08-12 14:43:00-04:00,OMER,positive
954800.0,Omeros Corporation Reports Q2 EPS of $(0.48) vs $(0.38) Est,2013-08-09 16:01:00-04:00,OMER,neutral
954801.0,"Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock",2013-08-01 12:09:00-04:00,OMER,positive
954803.0,"Omeros Spikes Higher, May be Attributed to Positive Wedbush Note",2013-08-01 11:11:00-04:00,OMER,positive
954804.0,European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302 ,2013-07-02 07:05:00-04:00,OMER,positive
954805.0,A Peek Into The Market Before The Trading Starts,2013-05-31 07:20:00-04:00,OMER,neutral
954806.0,Omeros Announces Positive Results from OMS824 Positron Emission Tomography Trial ,2013-05-31 07:05:00-04:00,OMER,positive
954807.0,Omeros Files Clinical Trial Application with CTA for Lead Antibody in MASP-2 Program ,2013-05-28 07:05:00-04:00,OMER,neutral
954808.0,Omeros Announces INDA for OMS824 in Huntington's Disease Cleared by FDA,2013-05-23 07:23:00-04:00,OMER,positive
954809.0,"Traders in Omeros Attributing Upside in Shares to Bullish Note from MLV & Co., Says Trend Higher 'Will Continue'",2013-05-14 15:58:00-04:00,OMER,positive
954810.0,"Omeros Corporation Reports Q1 EPS of $(0.40), Inline; Revenue of $1.10M vs $1.39M Est",2013-05-10 07:40:00-04:00,OMER,neutral
954811.0,Omeros Announces 3.9M Share Direct Offering of Common Stock at $4.14/Share,2013-05-09 19:31:00-04:00,OMER,positive
954812.0,"WBB Pounds the Table on Omeros Following Orphan Drug Status, Maintains Strong Buy Rating, $20 Target",2013-04-18 14:11:00-04:00,OMER,positive
954813.0,Omeros Files Orphan Drug Application with FDA for OMS721 ,2013-04-17 07:11:00-04:00,OMER,neutral
954814.0,"MLV & Co. Initiates Coverage on Omeros Corporation at Buy, Announces $14.00 PT",2013-04-15 09:06:00-04:00,OMER,neutral
954815.0,Omeros Announces Positive Data for Model for Studying Multiple Sclerosis ,2013-04-10 07:05:00-04:00,OMER,positive
954816.0,Omeros Announces Positive OMS721 Data ,2013-04-02 07:08:00-04:00,OMER,positive
954817.0,A Peek Into The Market Before The Trading Starts,2013-03-28 07:45:00-04:00,OMER,neutral
954818.0,Omeros Announces Toxicology Data from OMS721 Study Support Advancing MASP-2 Inhibitor into Clinical Trials ,2013-03-28 07:14:00-04:00,OMER,positive
954819.0,Stocks Hitting 52-Week Lows,2013-03-26 10:51:00-04:00,OMER,negative
954820.0,Omeros Completes PDE10 Phase 1 Multiple Ascending Dose Trial ,2013-03-26 07:06:00-04:00,OMER,neutral
954821.0,Stocks Hitting 52-Week Lows,2013-03-21 10:43:00-04:00,OMER,negative
954822.0,UPDATE: Canaccord Genuity Cuts PT to $13 on Omeros Corporation on Phase 3 Endpoint Miss  ,2012-12-28 09:12:00-05:00,OMER,negative
954823.0,"UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Omeros Corporation",2012-12-28 09:12:00-05:00,OMER,negative
954824.0,"Canaccord Genuity Maintains Buy on Omeros Corporation, Lowers PT to $13.00",2012-12-28 08:39:00-05:00,OMER,negative
954825.0,"Deutsche Bank Maintains Buy on Omeros Corporation, Lowers PT to $10.00",2012-12-28 08:39:00-05:00,OMER,negative
954826.0,"Stocks To Watch For December 28, 2012",2012-12-28 01:42:00-05:00,OMER,neutral
954827.0,Omeros Shares to Resume Trading at 4:30PM EST,2012-12-27 16:18:00-05:00,OMER,positive
954828.0,"Omeros Announces Phase 3 Results on OMS103HP, Says Symptons Subscale Didn't Meet Statistical Significance",2012-12-27 16:02:00-05:00,OMER,negative
954829.0,Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program,2012-12-06 07:33:00-05:00,OMER,positive
954830.0,Omeros Announces Promising Data from Phase 1 OMS824 Clinical Trial,2012-12-06 07:13:00-05:00,OMER,positive
954831.0,"From Earlier: Needham Upgrades Omeros Corporation to Buy, Announces $10.00 PT",2012-12-04 09:41:00-05:00,OMER,neutral
954832.0,Omerosoration Reports Q3 EPS $-0.51 vs $-0.34 Est; Revenues $1.41M vs $1.42M Est,2012-11-09 16:01:00-05:00,OMER,neutral
954833.0,Omeros Responds to Misleading Announcement  Concerning Settlement with Former CFO Richard J. Klein ,2012-11-09 07:04:00-05:00,OMER,negative
954834.0,"Wedbush Securities Maintains Omerosoration at Outperform, Raises PT from $19 to $20",2012-11-05 13:12:00-05:00,OMER,positive
954835.0,Omeros' Ophthalmology Announces Clinical Trial Data,2012-11-05 07:17:00-05:00,OMER,neutral
954836.0,UPDATE: Burrill Research Initiates Omeros Corporation at Market Outperform on Pipeline Strength  ,2012-10-15 08:00:00-04:00,OMER,positive
954837.0,"Burrill Research Initiates Coverage on Omerosoration at Market Outperform, Announces PT of $17",2012-10-15 06:10:00-04:00,OMER,neutral
954838.0,From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program,2012-10-02 09:19:00-04:00,OMER,positive
954839.0,Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program ,2012-09-06 07:04:00-04:00,OMER,neutral
954840.0,Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs,2012-08-15 07:10:00-04:00,OMER,neutral
954841.0,"Wedbush Securities Maintains Omerosoration at Outperform, Raises PT from $18 to $19",2012-07-18 10:05:00-04:00,OMER,positive
954842.0,"Wedbush Securities Maintains Omerosoration at Outperform, Raises PT from $18 to $19",2012-07-18 10:04:00-04:00,OMER,positive
954843.0,Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway ,2012-07-18 07:02:00-04:00,OMER,positive
954844.0,"Wedbush Securities Maintains Omeros Corporation at Outperform, Lowers PT from $20 to $18",2012-06-27 11:03:00-04:00,OMER,positive
954845.0,Omeros Down Nearly 20% After Pricing 3M Share Secondary ,2012-06-27 10:50:00-04:00,OMER,positive
954846.0,Omeros Prices $30M Public Offering of Common Stock at $10.25 per Share,2012-06-27 09:10:00-04:00,OMER,positive
954847.0,Benzinga's Top Pre-Market Losers,2012-06-27 08:26:00-04:00,OMER,negative
954848.0,Omeros Announces Proposed Public Offering of Common Stock ,2012-06-26 16:02:00-04:00,OMER,neutral
954849.0,Omeros Announces Initiation of Planned Pharmacokinetic Substudy in OMS302 Phase 3 Clinical Program ,2012-05-31 07:01:00-04:00,OMER,neutral
954850.0,Omeros Announces Enrollment in Second Phase 3 Clinical Trial Evaluating OMS302  ,2012-04-10 07:06:00-04:00,OMER,neutral
954851.0,A Peek Into The Market Before The Trading Starts,2012-03-29 07:16:00-04:00,OMER,neutral
954852.0,Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302 ,2012-03-29 07:01:00-04:00,OMER,neutral
954853.0,UPDATE: Deutsche Bank Upgrades Omeros,2012-03-14 10:18:00-04:00,OMER,neutral
954854.0,UPDATE: Canaccord Upgrades Omeros; Raises PT,2012-03-14 09:48:00-04:00,OMER,neutral
954855.0,"Canaccord Upgrades Omeros from Hold to Buy, Raises PT from $5 to $13",2012-03-14 08:22:00-04:00,OMER,neutral
954856.0,UPDATE: Rodman & Renshaw Raises PT to $16 on Omeros Corporation,2012-03-13 12:32:00-04:00,OMER,neutral
954857.0,"Wedbush Securities Maintains Omeros at Outperform, Raises PT from $15 to $17",2012-03-13 12:22:00-04:00,OMER,positive
954858.0,"Rodman & Renshaw Maintains Omerosoration at Market Outperform, Raises PT from $13 to $16",2012-03-13 10:59:00-04:00,OMER,neutral
954859.0,"Deutsche Bank Upgrades Omerosoration from Hold to Buy, Raises PT from $6 to $11",2012-03-13 09:31:00-04:00,OMER,neutral
954860.0,Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial ,2012-03-13 08:32:00-04:00,OMER,neutral
954861.0,Omeros Rises 41% on Positive Phase 3 Results,2012-03-13 08:31:00-04:00,OMER,positive
954862.0,Earnings Scheduled For March 12,2012-03-12 04:45:00-04:00,OMER,neutral
954863.0,Omeros Trading 6.9% Higher on Heavy Volume; Currently at $8.35,2012-03-06 14:47:00-05:00,OMER,neutral
954864.0,Omeros Awarded $1 Million NIDA Grant for NMUR2 Drug Development Program  ,2012-02-21 07:03:00-05:00,OMER,positive
954865.0,Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial  ,2012-02-07 07:01:00-05:00,OMER,neutral
954866.0,"Benzinga's Microcap Movers for Tuesday January 10, 2012",2012-01-10 22:00:00-05:00,OMER,neutral
954867.0,UPDATE: Rodman & Renshaw Upgrades Omeros to Outperform ,2011-12-05 09:54:00-05:00,OMER,neutral
954868.0,"Rodman & Renshaw Upgrades Omeros to Market Outperform, $13 PT",2011-12-05 07:32:00-05:00,OMER,neutral
954869.0,UPDATE: Wedbush Raises PT to $15 on Omeros Corp ,2011-11-30 08:25:00-05:00,OMER,neutral
954870.0,Wedbush Raises PT on Omeros to $15,2011-11-30 06:11:00-05:00,OMER,neutral
954871.0,Rodman & Renshaw Maintains Market Perform on Omeros Corp,2011-10-11 13:47:00-04:00,OMER,neutral
954872.0,Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302 ,2011-10-11 07:03:00-04:00,OMER,neutral
954873.0,Omeros Unlocks Orphan GPCR Family Linked to Metabolic and Psychotic Disorders ,2011-05-31 07:09:00-04:00,OMER,neutral
954874.0,Omeros Corporation Plummets 34.50% (OMER),2011-04-01 10:21:00-04:00,OMER,neutral
954875.0,Deutsche Bank Downgrades OMER To Hold,2011-04-01 06:22:00-04:00,OMER,neutral
954876.0,Deutsche Bank Reports Positive Surgery Data From Omeros,2011-03-24 07:51:00-04:00,OMER,positive
954877.0,Omeros Reports Q4 Results,2011-03-15 07:10:00-04:00,OMER,neutral
954878.0,Omeros Upgraded to Strong Buy (OMER),2010-10-26 09:59:00-04:00,OMER,positive
954879.0,Omeris (OMER) IPO Prices At Bottom of Range,2009-10-08 11:07:00-04:00,OMER,neutral
